165 related articles for article (PubMed ID: 38586420)
21. A novel signature based on autophagy-related lncRNA for prognostic prediction and candidate drugs for lung adenocarcinoma.
Gong Z; Li Q; Li J; Xie J; Wang W
Transl Cancer Res; 2022 Jan; 11(1):14-28. PubMed ID: 35261881
[TBL] [Abstract][Full Text] [Related]
22. Construction of a cancer-associated fibroblasts-related long non-coding RNA signature to predict prognosis and immune landscape in pancreatic adenocarcinoma.
Ye Y; Zhao Q; Wu Y; Wang G; Huang Y; Sun W; Zhang M
Front Genet; 2022; 13():989719. PubMed ID: 36212154
[No Abstract] [Full Text] [Related]
23. Identification and Validation of a Novel Necroptosis-Related Long Noncoding RNA Prognostic Signature for Lung Adenocarcinoma.
Zeng C; Yu H; Liu X; Liu Q; Jin J
Biomed Res Int; 2022; 2022():9710540. PubMed ID: 36330457
[TBL] [Abstract][Full Text] [Related]
24. Identification and validation of an autophagy-related long non-coding RNA signature as a prognostic biomarker for patients with lung adenocarcinoma.
Jiang A; Liu N; Bai S; Wang J; Gao H; Zheng X; Fu X; Ren M; Zhang X; Tian T; Ruan Z; Liang X; Yao Y
J Thorac Dis; 2021 Feb; 13(2):720-734. PubMed ID: 33717544
[TBL] [Abstract][Full Text] [Related]
25. Prognostic model and immunotherapy prediction based on molecular chaperone-related lncRNAs in lung adenocarcinoma.
Xu Y; Tao T; Li S; Tan S; Liu H; Zhu X
Front Genet; 2022; 13():975905. PubMed ID: 36313456
[No Abstract] [Full Text] [Related]
26. A neutrophil extracellular traps-associated lncRNA signature predicts the clinical outcomes in patients with lung adenocarcinoma.
Ding W; Li B; Zhang Y; He L; Su J
Front Genet; 2022; 13():1047231. PubMed ID: 36419832
[No Abstract] [Full Text] [Related]
27. An anoikis-related lncRNA signature is a useful tool for predicting the prognosis of patients with lung adenocarcinoma.
Jiang X; Gao YL; Li JY; Tong YY; Meng ZY; Yang SG; Zhu CT
Heliyon; 2023 Nov; 9(11):e22200. PubMed ID: 38053861
[TBL] [Abstract][Full Text] [Related]
28. Molecular typing and prognostic model of lung adenocarcinoma based on cuprotosis-related lncRNAs.
Zheng M; Zhou H; Xie J; Zhang H; Shen X; Zhu D
J Thorac Dis; 2022 Dec; 14(12):4828-4845. PubMed ID: 36647499
[TBL] [Abstract][Full Text] [Related]
29. A Novel Model Based on Genomic Instability-Associated Long Non-Coding RNAs for Predicting Prognosis and Response to Immunotherapy in Patients With Lung Adenocarcinoma.
Tu G; Peng W; Cai Q; Zhao Z; Peng X; He B; Zhang P; Shi S; Wang X
Front Genet; 2021; 12():720013. PubMed ID: 34777461
[No Abstract] [Full Text] [Related]
30. A prognostic and immunotherapy effectiveness model for pancreatic adenocarcinoma based on cuproptosis-related lncRNAs signature.
Zhang N; Yu X; Sun H; Zhao Y; Wu J; Liu G
Medicine (Baltimore); 2023 Oct; 102(42):e35167. PubMed ID: 37861553
[TBL] [Abstract][Full Text] [Related]
31. Development and validation of a prognostic risk signature for lung adenocarcinoma constructed by six ferroptosis, necroptosis, and pyroptosis-related lncRNAs.
Peng L; Ji J; Zhang C; Wu Z; Sun Y; Fan K; Du W; Liu A; Jiao W
J Thorac Dis; 2022 Oct; 14(10):3955-3974. PubMed ID: 36389299
[TBL] [Abstract][Full Text] [Related]
32. A cuproptosis-related lncRNAs risk model to predict prognosis and guide immunotherapy for lung adenocarcinoma.
Li Q; Wang T; Zhu J; Zhang A; Wu A; Zhou Y; Shi J
Ann Transl Med; 2023 Mar; 11(5):198. PubMed ID: 37007546
[TBL] [Abstract][Full Text] [Related]
33. A disulfidptosis-related lncRNA signature for predicting prognosis and evaluating the tumor immune microenvironment of lung adenocarcinoma.
Song Z; Cao X; Wang X; Li Y; Zhang W; Wang Y; Chen L
Sci Rep; 2024 Feb; 14(1):4621. PubMed ID: 38409243
[TBL] [Abstract][Full Text] [Related]
34. A Novel Aging-Related Prognostic lncRNA Signature Correlated with Immune Cell Infiltration and Response to Immunotherapy in Breast Cancer.
Liu Z; Ren C; Cai J; Yin B; Yuan J; Ding R; Ming W; Sun Y; Li Y
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110517
[TBL] [Abstract][Full Text] [Related]
35. A cuproptosis-related long non-coding RNA signature to predict the prognosis and immune microenvironment characterization for lung adenocarcinoma.
Ma S; Zhu J; Wang M; Zhu J; Wang W; Xiong Y; Jiang R; Seetharamu N; Abrão FC; Puthamohan VM; Liu L; Jiang T
Transl Lung Cancer Res; 2022 Oct; 11(10):2079-2093. PubMed ID: 36386454
[TBL] [Abstract][Full Text] [Related]
36. PANoptosis-related long non-coding RNA signature to predict the prognosis and immune landscapes of pancreatic adenocarcinoma.
Zhao Q; Ye Y; Zhang Q; Wu Y; Wang G; Gui Z; Zhang M
Biochem Biophys Rep; 2024 Mar; 37():101600. PubMed ID: 38371527
[TBL] [Abstract][Full Text] [Related]
37. Disulfidptosis‑related lncRNA prognosis model to predict survival therapeutic response prediction in lung adenocarcinoma.
Sun X; Li J; Gao X; Huang Y; Pang Z; Lv L; Li H; Liu H; Zhu L
Oncol Lett; 2024 Aug; 28(2):342. PubMed ID: 38855504
[TBL] [Abstract][Full Text] [Related]
38. Construction of an Immune-Related Six-lncRNA Signature to Predict the Outcomes, Immune Cell Infiltration, and Immunotherapy Response in Patients With Hepatocellular Carcinoma.
Zhou P; Lu Y; Zhang Y; Wang L
Front Oncol; 2021; 11():661758. PubMed ID: 34277410
[TBL] [Abstract][Full Text] [Related]
39. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
40. A cuproptosis-related lncRNA signature for predicting prognosis and immune response in hepatocellular carcinoma.
Wu J; Yao J; Jia S; Yao X; Shao J; Cao W; Ma S; Yao X; Li H
Heliyon; 2023 Sep; 9(9):e19352. PubMed ID: 37810122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
